Aardvark Therapeutics, Inc. (AARD) shareholders
Close on Nov 17, 2026Market cap $25.17MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Xiangmin Cui Joint filing with Decheng Capital Global Life Sciences Fund IV, L.P. (13.80%), Decheng Capital Management IV (Cayman), LLC (13.80%) | 3,917,299 | 18.30% | 13G (passive) | Feb 14, 2025 |
| Jane Wu Lee Joint filing with Tien-Li Lee (13.70%) | 2,983,724 | 13.70% | 13G (passive) | Mar 31, 2025 |
| Vickers Venture Fund VI Pte. Ltd. Joint filing with Dr. Finian Tan (8.69%), Christopher Michael Ho (7.92%) | 2,050,902 | 9.58% | 13G (passive) | Feb 12, 2025 |
| Kenneth Griffin Joint filing with Citadel Advisors LLC (5.40%), Citadel Advisors Holdings LP (5.40%) and 1 more | 1,192,971 | 5.60% | 13G (passive) | Feb 14, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AARD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Decheng Capital LLC | 3,917,299 | 17.90% | $22.56M | – | 3.08% |
| Citadel Advisors LLC | 1,283,166 | 5.86% | $7.39M | +40,389 | 0.00% |
| Laurion Capital Management LP | 1,034,459 | 4.73% | $5.96M | – | 0.15% |
| Vanguard Capital Management LLC | 562,877 | 2.57% | $3.24M | +8,776 | 0.00% |
| Aqr Capital Management LLC | 480,249 | 2.19% | $2.77M | +345,754 | 0.00% |
| EcoR1 Capital, LLC | 396,194 | 1.81% | $2.28M | New | 0.11% |
| Adage Capital Partners Gp, L.L.C. | 300,000 | 1.37% | $1.73M | – | 0.00% |
| Cantor Fitzgerald, L. P. | 233,164 | 1.07% | $1.34M | +166,482 | 0.01% |
| BlackRock, Inc. | 187,045 | 0.85% | $1.08M | −605,526 | 0.00% |
| Geode Capital Management, LLC | 149,844 | 0.68% | $863.53K | −159,605 | 0.00% |
| Two Sigma Investments, LP | 108,377 | 0.50% | $624.25K | −54,978 | 0.00% |
| Raymond James Financial Inc | 79,284 | 0.36% | $456.68K | +68,394 | 0.00% |
| Vanguard Fiduciary Trust Co | 75,172 | 0.34% | $432.99K | −8,038 | 0.00% |
| Woodline Partners LP | 72,429 | 0.33% | $417.19K | – | 0.00% |
| Millennium Management LLC | 69,948 | 0.32% | $402.90K | −28,386 | 0.00% |
| State Street Corp | 59,273 | 0.27% | $341.41K | −140,049 | 0.00% |
| J. Goldman & Co LP | 40,500 | 0.19% | $233.28K | New | 0.01% |
| Ieq Capital, LLC | 38,382 | 0.18% | $221.08K | +21,897 | 0.00% |
| UBS Group AG | 35,639 | 0.16% | $205.28K | −122,249 | 0.00% |
| Morgan Stanley | 30,177 | 0.14% | $173.82K | +12,615 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 10M | 43.6% | 19 / 20 | 24 / 24 | 1M | 2M |
| Q1 2026 | 79 | 10M | 46.6% | 32 / 17 | 23 / 18 | 2M | 2M |
| Q4 2025 | 66 | 11M | 49.1% | 23 / 27 | 9 / 6 | 2M | 1M |
| Q3 2025 | 49 | 9M | 43.2% | 15 / 20 | 7 / 1 | 1M | 1M |
| Q2 2025 | 35 | 9M | 40.7% | 17 / 13 | 3 / 9 | 1M | 1M |
| Q1 2025 | 27 | 9M | 39.7% | 27 / 0 | 0 / 0 | 9M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
78 funds held AARD in Q1 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AARD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 408,670 | 1.87% | $2.35M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 140,389 | 0.64% | $808.64K | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 89,124 | 0.41% | $513.35K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 66,747 | 0.30% | $274.33K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 64,981 | 0.30% | $267.07K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 42,615 | 0.19% | $245.46K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 24,000 | 0.11% | $138.24K | 0.09% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 22,633 | 0.10% | $93.02K | 0.00% | May 31, 2026 |
| ALPS Medical Breakthroughs ETF | 22,439 | 0.10% | $92.22K | 0.06% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 18,735 | 0.09% | $77.00K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 15,483 | 0.07% | $63.64K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 8,867 | 0.04% | $51.07K | 0.00% | Jun 30, 2026 |
| VIP Disciplined Small Cap Portfolio | 7,980 | 0.04% | $45.96K | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 6,719 | 0.03% | $27.62K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 4,951 | 0.02% | $28.52K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tien-Li Lee | Chief Executive Officer, Director, 10% owner | 3,025,641 | 13.83% | Nov 10, 2026 |
| Manasi Jaiman | Chief Medical Officer | – | – | Nov 10, 2026 |
| Nelson Sun | See Remarks | 35,475 | 0.16% | Nov 10, 2026 |
| Bryan Jones | Chief Operating Officer | 1,250 | 0.01% | Oct 16, 2025 |
| Zhongwei Zhang | Director | – | – | Oct 8, 2026 |
| Jeffrey Chi | Director | 133,364 | 0.61% | Aug 21, 2026 |
| Susan E. Graf | Director | – | – | Aug 21, 2026 |
| Roy D. Baynes | Director | – | – | Aug 21, 2026 |
| Victor Edward Tong Jr | Director | – | – | Aug 21, 2026 |
| Decheng Capital Management IV (Cayman), LLC | 10% owner | – | – | Feb 19, 2025 |
| Venture Fund VI Pte Ltd Vickers | 10% owner | 2,050,902 | 9.37% | Feb 19, 2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 10% owner | 3,292,299 | 15.04% | Feb 19, 2025 |
| Decheng Capital Global Healthcare Fund (Master), LP | 10% owner | – | – | Feb 19, 2025 |
| Decheng Capital Global Healthcare GP, LLC | 10% owner | – | – | Feb 19, 2025 |
| Xiangmin Cui | 10% owner | – | – | Feb 19, 2025 |
| Cormorant Asset Management, LP | – | – | – | Feb 19, 2025 |
| Bihua Chen | – | 800,189 | 3.66% | Feb 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nelson Sun See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −62,000 | $5.18 | $321.16K | 35,475 |
| Nelson Sun See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −14,754 | $5.00 | $73.77K | 97,475 |
| Nelson Sun Chief Financial Officer | Dec 11, 2025 | Buy | +3,000 | $14.40 | $43.20K | 108,484 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Dec 11, 2025 | Buy | +7,000 | $14.49 | $101.43K | 1,551,613 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Oct 15, 2025 | Option exercise | +1,229 | $4.24 | $5.21K | 1,544,613 |
| Bryan Jones Chief Operating Officer | Oct 15, 2025 | Option exercise | +1,250 | $4.24 | $5.30K | 1,250 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Sep 15, 2025 | Buy | +3,500 | $9.94 | $34.79K | 1,543,384 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Sep 15, 2025 | Buy | +6,500 | $9.51 | $61.82K | 1,539,884 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Sep 12, 2025 | Buy | +5,000 | $8.50 | $42.50K | 1,533,384 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Sep 11, 2025 | Buy | +6,000 | $7.82 | $46.92K | 1,528,384 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Sep 10, 2025 | Buy | +9,000 | $7.91 | $71.19K | 1,522,384 |
| Nelson Sun Chief Financial Officer | Sep 9, 2025 | Buy | +6,000 | $8.07 | $48.42K | 105,484 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Aug 28, 2025 | Option exercise | +17,209 | $4.24 | $72.97K | 1,513,384 |
| Bihua Chen – | Feb 14, 2025 | Conversion | +800,189 | – | – | 800,189 |
| Bihua Chen – | Feb 14, 2025 | Buy | +187,500 | $16.00 | $3.00M | 987,689 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Feb 14, 2025 | Conversion | +41,303 | – | – | 1,479,633 |
| Tien-Li Lee Chief Executive Officer, Director, 10% owner | Feb 14, 2025 | Buy | +16,542 | $16.00 | $264.67K | 1,496,175 |
| Venture Fund VI Pte Ltd Vickers 10% owner | Feb 14, 2025 | Conversion | +413,491 | – | – | 2,050,902 |
| Venture Fund VI Pte Ltd Vickers 10% owner | Feb 14, 2025 | Conversion | +1,637,411 | – | – | 1,637,411 |
| Jeffrey Chi Director | Feb 14, 2025 | Conversion | +133,364 | – | – | 133,364 |
| Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Feb 14, 2025 | Conversion | +333,412 | – | – | 333,412 |
| Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Feb 14, 2025 | Buy | +625,000 | $16.00 | $10.00M | 2,958,887 |
| Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Feb 14, 2025 | Buy | +625,000 | $16.00 | $10.00M | 958,412 |
| Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Feb 14, 2025 | Conversion | +2,333,887 | – | – | 2,333,887 |
| Nelson Sun Chief Financial Officer | Feb 14, 2025 | Conversion | +7,001 | – | – | 89,484 |
| Nelson Sun Chief Financial Officer | Feb 14, 2025 | Buy | +10,000 | $16.00 | $160.00K | 99,484 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aardvark Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 841 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nelson Sun Officer | Sep 11, 2026 | 33,911 | $169.89K | Sep 11, 2026 | Previously Exercised Stock Options |
| Nelson Sun Officer | Sep 10, 2026 | 42,843 | $210.79K | Sep 10, 2026 | Open Market Purchase |
| Vickers Vent Glb Deep-Tech Fnd I LP Director, 10% Stockholder | Sep 15, 2025 | 10,360 | $93.41K | Sep 15, 2025 | Private Acquisition from Issuer/Affiliate |
| Vickers Vent Glb Deep-Tech Fnd I LP Director, 10% Stockholder | Sep 2, 2025 | 20,000 | $170.12K | Sep 2, 2025 | Private Acquisition from Issuer/Affiliate |
| Vickers Vent Glb Deep-Tech Fnd I LP Director, 10% Stockholder | Aug 28, 2025 | 27,691 | $241.57K | Aug 28, 2025 | Private Acquisition from Issuer/Affiliate |
See a number that looks wrong?